Axisresearch
List of Categories
- Aerospace & Defense
- Agriculture
- Animal Nutrition & Wellness
- Automation
- Automotive
- Chemical & Materials
- Consumer Goods and Services
- Electronics
- Energy & Mining
- Financial Services & Investment Intelligence
- Food & Beverage
- Healthcare
- Heavy Industry
- Home & Property Improvement
- Information & Communications Technology
- Investment Opportunities
- Manufacturing
- NEO
- Others
- Packaging
- Retail
- Technology & Media
- Transportation & Logistics
Sorted by Name
Publishers
Countries
Human Microbiome Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 116 pages | Published: 10-06-2019 |
- Healthcare
- Mordor Intelligence
- 116 pages
- Published: 10-06-2019
Market Overview
The global human microbiome market is expected to show a CAGR of 22.60% during the forecast period. The key factors propelling the growth of this market are increasing incidence of lifestyle-related diseases and growing geriatric population.
The rising incidence of lifestyle-related diseases, globally, is a strong driver of the human microbiome market, as therapeutics may provide an alternative route to tackle significant healthcare challenges, such as obesity. The increasing occurrence of autoimmune disorders and antibiotic resistance are also important areas, which are in great need of fresh treatment approaches, and for which, microbiome therapies may have a significant impact over the next few years. With advancements in precision medicine, personalized nutrition is also playing a crucial role. Microbiome technologies strive for novel developments in the area. Cardiovascular diseases (CVD) continue to be the major cause of mortality, representing about 30% of all deaths, worldwide. Lifestyle-related diseases, like hypertension, diabetes mellitus, dyslipidaemia, and overweight/obesity, are the major risk factors for the development of CVD. With rapid economic development and increasing westernization of lifestyles in the past few decades, the prevalence of these diseases has reached alarming proportions in the recent years, which is expected to boost the growth of the human microbiome market.
Scope of the Report
The global human microbiome market comprises various therapeutic and diagnostic products that include human microbiota. The market also includes disease indication. The size of the market has been estimated based on the revenues generated from therapies and diagnostic techniques.
Key Market Trends
Therapeutic Applications is Expected to hold the Highest Market Share
The therapeutic applications segment is expected to have the largest market share during the forecast period and is likely to register a CAGR of 22.93%.
The microbiome-based products for therapeutics are still in the development phase. There are a number of organizations that are developing products across various disease areas in the human microbiome space. Companies have developed their own proprietary technology platforms and innovative approaches to microbiome-based treatment. The most common strategy deployed for a variety of products is the use of natural, live bacteria, either as a single agent or in a mixture form. Some companies are engineering bacteria and are programing them to take over certain physiologic functions to tackle rare disorders.
North America Dominates the Market and Expected to do Same in the Forecast Period
North America currently dominates the market for human microbiome and is expected to continue its stronghold for a few more years. In the North American region, the United States holds the largest market share. It is also the largest market for microbiome-based products, globally. The growth of the market is majorly due to the high level of awareness about the beneficial aspects of microbiome-based products and initiatives, like the NIH human microbiome project, which have been responsible for generating a holistic understanding of concepts, like metagenomic and whole genome sequencing.
Competitive Landscape
The human microbiome market is less competitive currently and consists of several players that are coming up with products. Companies, like Yakult, DuPont, Series Therapeutics, Second Genome, and Synthetic Biologics, hold substantial shares in the market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence of Lifestyle-related Diseases
4.2.2 Growing Geriatric Population
4.3 Market Restraints
4.3.1 Lack of Comprehensive Research
4.3.2 Stringent Government Regulations
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Application
5.1.1 Therapeutics
5.1.2 Diagnostics
5.2 Disease
5.2.1 Obesity
5.2.2 Diabetes
5.2.3 Autoimmune Disorder
5.2.4 Cancer
5.2.5 Gastrointestinal Disorders
5.2.6 Central Nervous System Disorders
5.2.7 Other Diseases
5.3 Product
5.3.1 Probiotics
5.3.2 Prebiotics
5.3.3 Symboitics
5.3.4 Other Products
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Enterome Bioscience
6.1.2 Yakult
6.1.3 DuPont
6.1.4 Seres Therapeutics
6.1.5 Vithera Pharmaceuticals
6.1.6 Second Genome Inc.
6.1.7 Synthetic Biologics Inc.
6.1.8 Vedanta Biosciences Inc.
6.1.9 Osel Inc.
6.1.10 Synlogic Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
Application
Therapeutics
Diagnostics
Disease
Obesity
Diabetes
Autoimmune Disorder
Cancer
Gastrointestinal Disorders
Central Nervous System Disorders
Other Diseases
Product
Probiotics
Prebiotics
Symboitics
Other Products
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Market Overview
The global human microbiome market is expected to show a CAGR of 22.60% during the forecast period. The key factors propelling the growth of this market are increasing incidence of lifestyle-related diseases and growing geriatric population.
The rising incidence of lifestyle-related diseases, globally, is a strong driver of the human microbiome market, as therapeutics may provide an alternative route to tackle significant healthcare challenges, such as obesity. The increasing occurrence of autoimmune disorders and antibiotic resistance are also important areas, which are in great need of fresh treatment approaches, and for which, microbiome therapies may have a significant impact over the next few years. With advancements in precision medicine, personalized nutrition is also playing a crucial role. Microbiome technologies strive for novel developments in the area. Cardiovascular diseases (CVD) continue to be the major cause of mortality, representing about 30% of all deaths, worldwide. Lifestyle-related diseases, like hypertension, diabetes mellitus, dyslipidaemia, and overweight/obesity, are the major risk factors for the development of CVD. With rapid economic development and increasing westernization of lifestyles in the past few decades, the prevalence of these diseases has reached alarming proportions in the recent years, which is expected to boost the growth of the human microbiome market.
Scope of the Report
The global human microbiome market comprises various therapeutic and diagnostic products that include human microbiota. The market also includes disease indication. The size of the market has been estimated based on the revenues generated from therapies and diagnostic techniques.
Key Market Trends
Therapeutic Applications is Expected to hold the Highest Market Share
The therapeutic applications segment is expected to have the largest market share during the forecast period and is likely to register a CAGR of 22.93%.
The microbiome-based products for therapeutics are still in the development phase. There are a number of organizations that are developing products across various disease areas in the human microbiome space. Companies have developed their own proprietary technology platforms and innovative approaches to microbiome-based treatment. The most common strategy deployed for a variety of products is the use of natural, live bacteria, either as a single agent or in a mixture form. Some companies are engineering bacteria and are programing them to take over certain physiologic functions to tackle rare disorders.
North America Dominates the Market and Expected to do Same in the Forecast Period
North America currently dominates the market for human microbiome and is expected to continue its stronghold for a few more years. In the North American region, the United States holds the largest market share. It is also the largest market for microbiome-based products, globally. The growth of the market is majorly due to the high level of awareness about the beneficial aspects of microbiome-based products and initiatives, like the NIH human microbiome project, which have been responsible for generating a holistic understanding of concepts, like metagenomic and whole genome sequencing.
Competitive Landscape
The human microbiome market is less competitive currently and consists of several players that are coming up with products. Companies, like Yakult, DuPont, Series Therapeutics, Second Genome, and Synthetic Biologics, hold substantial shares in the market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence of Lifestyle-related Diseases
4.2.2 Growing Geriatric Population
4.3 Market Restraints
4.3.1 Lack of Comprehensive Research
4.3.2 Stringent Government Regulations
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Application
5.1.1 Therapeutics
5.1.2 Diagnostics
5.2 Disease
5.2.1 Obesity
5.2.2 Diabetes
5.2.3 Autoimmune Disorder
5.2.4 Cancer
5.2.5 Gastrointestinal Disorders
5.2.6 Central Nervous System Disorders
5.2.7 Other Diseases
5.3 Product
5.3.1 Probiotics
5.3.2 Prebiotics
5.3.3 Symboitics
5.3.4 Other Products
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Enterome Bioscience
6.1.2 Yakult
6.1.3 DuPont
6.1.4 Seres Therapeutics
6.1.5 Vithera Pharmaceuticals
6.1.6 Second Genome Inc.
6.1.7 Synthetic Biologics Inc.
6.1.8 Vedanta Biosciences Inc.
6.1.9 Osel Inc.
6.1.10 Synlogic Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
Application
Therapeutics
Diagnostics
isease
5.2.1 Obesity
5.2.2 Diabetes
5.2.3 Autoimmune Disorder
5.2.4 Cancer
5.2.5 Gastrointestinal Disorders
5.2.6 Central Nervous System Disorders
5.2.7 Other Diseases
5.3 Product
5.3.1 Probiotics
5.3.2 Prebiotics
5.3.3 Symboitics
5.3.4 Other Products
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Enterome Bioscience
6.1.2 Yakult
6.1.3 DuPont
6.1.4 Seres Therapeutics
6.1.5 Vithera Pharmaceuticals
6.1.6 Second Genome Inc.
6.1.7 Synthetic Biologics Inc.
6.1.8 Vedanta Biosciences Inc.
6.1.9 Osel Inc.
6.1.10 Synlogic Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Hyperbaric Oxygen Therapy (HBOT) Devices Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 111 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 111 pages
- Published: 07-06-2019
Market Overview
The hyperbaric oxygen therapy (HBOT) devices market is majorly driven by the rising prevalence of acute and chronic wounds, widening the application of HBOT devices in cosmetic procedures and wound healing, and technological advancements.
HBOT devices are used in chronic problem wounds caused by diabetes, venous or arterial insufficiency, crush injuries, and wounds/tissue damage caused by the late effects of radiation therapy. The chronic wounds impose a significant burden on the individual, the healthcare system, and the society as a whole. According to the estimates of the National Health Services (NHS), 1.5% of the UK population is estimated to have a leg ulcer. Furthermore, as per the NHS Benchmarking 2016 annual audit, approximately 39% of a district nursing service workload is attributed to wound care. The annual cost of managing wounds in the NHS and associated comorbidities has been estimated to be EUR 5.3 billion, which is more than what is on par with the obesity treatment costs, according to the study published in 2017 by Guest J, Venous Leg Ulcer Management in Clinical Practice in the UK: Costs and Outcomes. Thus, the rising incidences and prevalence of acute and chronic wounds are expected to drive the growth of the hyperbaric oxygen therapy (HBOT) devices market over the forecast period.
Scope of the Report
As per the scope of this report, the term hyperbaric oxygen therapy implicates breathing oxygen in pressurized chambers, where the atmospheric pressure is thrice higher than normal, thus, allowing the lungs to absorb three times more oxygen than in normal air pressure. Hyperbaric oxygen therapy augments the quantity of oxygen, which may improve vital tissue function in recovery from injuries and fight infection.
Key Market Trends
Monoplace HBOT is the Segment Under Application that is Expected to Grow Fastest During the Forecast Period
The monoplace HBOT segment held a maximum share in 2018, due to factors, like commercial availability of monoplace systems and high adoption of such devices, due to ease of handling and less requirement of hospital gas supply. The market is majorly dominated by few products, such as BARA-MEDXD, BARA-MED, BARA-MED Select by ETC Hyperbaric Chambers (Environmental Tectonics Corporation); PAH-S1 Hyperbaric Chamber & PAH-S1-3800 Hyperbaric Chamber by Pan-America Hyperbarics Inc.
The monoplace HBOT devices segment is expected to register a high growth rate during the forecast period, due to the rising demand for monoplace systems in hospitals and clinics, due to their higher availability in the market, along with ease in installation.
North American Region Holds the Largest Share of the Market Currently and is Believed to Follow the Same Trend over the Forecast Period
The North American region is expected to dominate the market, owing to factors, such as rising disposable income, increasing population, and the rising need for wound healing treatment, which have impelled the demand for HBOT in the region. According to the National Institutes of Health, human skin wound is a significant indirect threat to the economy, as the government takes responsibility for the treatment of the public. This has led the government to invest huge amounts of money toward developing effective treatment methods. Research in the United States has revealed that the incidence of non-healing cutaneous wounds is about 5 to 7 million per year, in the country. The relative spending for these wounds is about USD 25 billion. The cost burden to the US healthcare system has been so severe that the medical services and centers for medical care have made amendments to the reimbursement policy for wound care, providing economic incentives for hospitals, in order to improve and reduce costs. All of the aforementioned factors are expected to propel the growth of the hyperbaric oxygen therapy (HBOT) devices market.
Competitive Landscape
The hyperbaric oxygen therapy (HBOT) devices market is moderately competitive and consists of several major players. The companies are implementing certain strategic initiatives, such as mergers, new product launches, acquisitions, and partnerships, which help them in strengthening their market positions.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Acute and Chronic Wounds
4.2.2 Widening Application of HBOT Devices in Cosmetic Procedures and Wound Healing
4.2.3 Technological Advancements
4.3 Market Restraints
4.3.1 High Cost of Hyperbaric Oxygen Therapy
4.3.2 Widening Gap Between Off-label Uses and FDA-approved Uses
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Application
5.1.1 Decompression Sickness
5.1.2 Diabetic Foot Ulcers
5.1.3 Gas Embolism
5.1.4 Infection Treatment
5.1.5 Wound Healing
5.1.6 Other Applications
5.2 Product Type
5.2.1 Monoplace HBOT Devices
5.2.2 Multiplace HBOT Devices
5.2.3 Topical HBOT Devices
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Environmental Tectonics Corporation
6.1.2 Fink Engineering
6.1.3 Gulf Coast Hyperbarics Inc.
6.1.4 HAUX-LIFE-SUPPORT GmbH
6.1.5 Hearmec Co. Ltd
6.1.6 Hyperbaric SAC
6.1.7 IHC Hytech BV
6.1.8 HYPERBARIC MODULAR SYSTEMS INC. (HMS)
6.1.9 Sechrist Industries Inc.
6.1.10 SOS Medical Group Ltd
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
Application
Decompression Sickness
Diabetic Foot Ulcers
Gas Embolism
Infection Treatment
Wound Healing
Other Applications
Product Type
Monoplace HBOT Devices
Multiplace HBOT Devices
Topical HBOT Devices
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
In-Vitro Diagnostic Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 115 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 115 pages
- Published: 07-06-2019
Market Overview
Global In-Vitro Diagnostic market was valued at USD 59,272.87 million in 2018 and is estimated to be valued at USD 82,626.27 million in 2024, witnessing a CAGR of 4.81%. The growth of the global IVD market can be attributed to the high prevalence of chronic and infectious diseases. Chronic diseases are a growing global challenge, and according to WHO estimates, account for approximately 60% of all deaths, worldwide. The current market is also growing due to the use of advanced technologies in the IVD market. There has been a paradigm shift from traditional diagnostics to a new generation diagnostics of that works at the gene level. This was made possible by the inclusion of advanced technologies, such as genetic testing, molecular diagnostics, polymerase chain reaction (PCR) and next-generation sequencing (NGS).
Scope of the Report
As per the scope of this report, in vitro diagnostics involves medical devices and consumables that are utilized to perform in vitro tests on various biological samples. They are used for the diagnosis of various medical conditions, such as chronic diseases.
Key Market Trends
Reagent is Expected to hold its Highest Market Share in the Product Segment
In the product segment of the In-Vitro Diagnostic market, the reagent is believed to have the largest market size and is expected to witness a CAGR of 4.8% in the forecast period.
The reagent segment of the market studied includes chemical, biological, or immunological components, solutions, or preparations intended by the manufacturer to be used during the in-vitro diagnosis process. Given the high cost of many diagnostic platforms, it is common for manufacturers to lease equipment instead of selling technology outright to end users. In these arrangements, the lease is tied to contracts to purchase associated reagents or assays for the equipment over the life of the contract. Many diagnostic companies have in excess of 75% of sales from consumables such as assays and reagents, and such agreements guarantee the generation of cyclic revenues associated with the sale of reagents and other consumables.
Many developing countries have established local immunoassay reagent programs to manufacture low-cost, high-quality immunoassay reagents. Kits from these projects are now beginning to become available and are likely to fuel the market expansion.
North America Dominates the Market and is Expected to continue its Dominance in the Forecast Period
North America currently dominates the market for In-Vitro Diagnostic and is expected to continue its stronghold for a few more years. This region is expected to increase its market share in the future owing to the well-established healthcare industry and rising prevalence of the chronic diseases in the region. The United States holds the majority of the market in the North America region; this is due to the rising healthcare expenditure, along with rapid adoption of point-of-care testing.
Competitive Landscape
The In-Vitro Diagnostic market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with technological advancement and product innovation, mid-size to smaller companies are increasing their market presence by introducing new products at lesser prices. Companies like Thermo Fischer Scientific Inc., Qiagen N.V., Bio-Rad Laboratories, Inc., Siemens Healthcare GmbH and F. Hoffmann-La Roche AG. holds the substantial market share in the In-Vitro Diagnostic market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 High Prevalence of Chronic Diseases
4.2.2 Increasing Use of Point-of-care (POC) Diagnostics
4.2.3 Advanced Technologies
4.2.4 Increasing Awareness and Acceptance of Personalized Medicine and Companion Diagnostics
4.3 Market Restraints
4.3.1 Stringent Regulations
4.3.2 Cumbersome Reimbursement Procedures
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Technique
5.1.1 Histochemistry
5.1.2 Molecular Diagnostics
5.1.3 Hematology
5.1.4 POC Testing
5.1.5 Self-blood Glucose Testing
5.1.6 Immunochemistry
5.1.7 Other Techniques
5.2 By Product
5.2.1 Instrument
5.2.2 Reagent
5.2.3 Others
5.3 By Usability
5.3.1 Disposable IVD Devices
5.3.2 Reusable IVD Devices
5.4 By Application
5.4.1 Infectious Disease
5.4.2 Diabetes
5.4.3 Cancer/Oncology
5.4.4 Cardiology
5.4.5 Autoimmune Disease
5.4.6 Nephrology
5.4.7 Drug Testing
5.4.8 Other Applications
5.5 By End Users
5.5.1 Academia
5.5.2 Laboratories
5.5.3 Hospitals & Clinics
5.5.4 Other End Users
5.6 Geography
5.6.1 North America
5.6.1.1 US
5.6.1.2 Canada
5.6.1.3 Mexico
5.6.2 Europe
5.6.2.1 Germany
5.6.2.2 UK
5.6.2.3 France
5.6.2.4 Italy
5.6.2.5 Spain
5.6.2.6 Rest of Europe
5.6.3 Asia Pacific
5.6.3.1 China
5.6.3.2 Japan
5.6.3.3 India
5.6.3.4 Australia
5.6.3.5 South Korea
5.6.3.6 Rest of Asia-Pacific
5.6.4 Middle East and Africa
5.6.4.1 GCC
5.6.4.2 South Africa
5.6.4.3 Rest of Middle East and Africa
5.6.5 South America
5.6.5.1 Brazil
5.6.5.2 Argentina
5.6.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 BioMérieux
6.1.2 Danaher Corporation
6.1.3 F. Hoffmann-La Roche AG
6.1.4 Becton, Dickinson and Company
6.1.5 Bio-Rad Laboratories, Inc.
6.1.6 Abbott Laboratories
6.1.7 Arkray Inc.
6.1.8 Sysmex Corporation
6.1.9 Ortho Clinical Diagnostics
6.1.10 Siemens Healthcare GmbH
6.1.11 Thermo Fischer Scientific Inc.
6.1.12 QIAGEN N.V.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Technique
Histochemistry
Molecular Diagnostics
Hematology
POC Testing
Self-blood Glucose Testing
Immunochemistry
Other Techniques
By Product
Instrument
Reagent
Others
By Usability
Disposable IVD Devices
Reusable IVD Devices
By Application
Infectious Disease
Diabetes
Cancer/Oncology
Cardiology
Autoimmune Disease
Nephrology
Drug Testing
Other Applications
By End Users
Academia
Laboratories
Hospitals & Clinics
Other End Users
Geography
North America
US
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
India Enteral Feeding Devices Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 72 pages | Published: 10-06-2019 |
- Healthcare
- Mordor Intelligence
- 72 pages
- Published: 10-06-2019
Market Overview
The major factors for the growth of the Indian enteral feeding devices market include the growing geriatric population, increasing premature birth rate, increasing adoption of enteral nutrition, and the high prevalence of chronic diseases. These factors are expected to further contribute to the growth of enteral feeding devices market during the forecast period.
The burden of chronic diseases is growing rapidly in India. According to the World Health Organization (WHO), every second person in India dies from non-communicable diseases. Chronic diseases in the country were projected to account for 53% of all deaths in 2015. In 2016, over 20% of the country’s population was suffering from at least one non-communicable disease (NCD). According to the World Health Survey data, more than 20% of the Indian population smokes daily, which is a major contributor to the increasing prevalence and incidence of chronic diseases. India is among the top three countries with a high incidence of diabetes. In addition, sedentary lifestyles and obesity are the other factors responsible for the high prevalence of diabetes. Chronic patients, who are incapable of taking food, require a good supply of nutrition through enteral feeding, which augments the demand for enteral feeding devices. Therefore, the high prevalence of chronic diseases in India is projected to drive the growth of the market studied, over the forecast period.
In India, several hospitalized patients are malnourished, thus resulting in an increase in morbidity and mortality rates. Patients suffering from malnutrition require nutritional support to fasten their recovery. The enteral route is preferred for patients who cannot increase their oral intake, in order to meet their nutritional requirements. Enteral nutrition has fewer side effects and is cost effective, when compared to other modes of nutrition supply. The increasing incidence of chronic diseases, growing patient pool, and increasing ageing population are leading to an increase in the adoption of enteral nutrition among the Indian population; thus, driving the growth of the market studied, over the forecast period.
Scope of the Report
As per the scope of this report, enteral feeding devices refer to the delivery of a nutrient-enriched feed, containing protein, carbohydrate, fat, water, minerals, and vitamins, directly into the stomach, duodenum, or jejunum. It is used for people with functional gastrointestinal (GI) tract, who are not able to ingest foods orally to meet their nutrient demand. Enteral feeding plays a major role in the management of patients with poor voluntary intake, chronic neurological or mechanical dysphagia, gut dysfunction, and in patients who are critically ill.
Key Market Trends
Oncology is the Segment under Application that is Expected to Grow Fastest during the Forecast Period
The major factor driving the growth of the oncology segment is the rising prevalence of cancer in India. Cancer treatment causes many complications and side effects in patients, including mucositis sores in the mouth, difficulty in chewing and swallowing solid food, altered saliva level, making it difficult to swallow. Cancer patients suffer from severe weight loss, as they cannot take proper food, resulting in the shortage of nutrition in the body. According to the estimates of Globocan 2018, there are likely to be 1,157,294 new cases of cancer, and breast, lip, oral cavity, cervical, and lung cancers are the major types of cancers, in India. Oral cancer is the most common type of cancer in men and breast cancer in women. Furthermore, as per the data published by the ICMR (Indian Council of Medical Research), in 2016, India had 14 lakh cancer patients, and this number is expected to increase. Thus, the presence of a huge patient pool is likely to create tremendous opportunities for the market.
Competitive Landscape
The Indian enteral feeding devices market is dominated by few global players. These global enterprises are competing with each other on various fronts, such as the introduction of new products, increasing geographical penetration, and enhancing distribution channels. The high competition is expected to drive the merger and acquisition activity, thereby, leading to market consolidation, in a few business segments.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Geriatric Population
4.2.2 Increasing Premature Birth Rate
4.2.3 Increasing Adoption of Enteral Nutrition
4.2.4 High Prevalence of Chronic Diseases
4.3 Market Restraints
4.3.1 Complications Associated with Enteral Feeding Tubes
4.3.2 Low-cost Products from Small Players
4.3.3 Inadvertent Dislodgment of Tubes
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product
5.1.1 Enteral Feeding Pump
5.1.2 Enteral Feeding Tube
5.1.2.1 Nasoenteric Feeding Tube
5.1.2.2 Oroenteric Feeding Tube
5.1.2.3 Enterostomy Tube
5.1.2.3.1 Standard Tube
5.1.2.3.2 Low-profile Tube
5.1.2.4 Other Tubes
5.1.3 Other Devices
5.2 By Age Group
5.2.1 Adult
5.2.2 Pediatric
5.3 By End User
5.3.1 Hospital
5.3.2 Ambulatory Care Service
5.3.3 Other End Users
5.4 By Application
5.4.1 Oncology
5.4.2 Gastroenterology
5.4.3 Diabetes
5.4.4 Neurological Disorder
5.4.5 Hypermetabolism
5.4.6 Other Applications
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 B Braun Melsungen AG
6.1.3 Boston Scientific Corporation
6.1.4 Becton, Dickinson and Company
6.1.5 CONMED Corporation
6.1.6 Cook Medical Incorporated
6.1.7 Fresenius Se & Co. KGaA
6.1.8 Halyard Health Inc.
6.1.9 Cardinal Health
6.1.10 Nestle SA
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Product
Enteral Feeding Pump
Enteral Feeding Tube
Nasoenteric Feeding Tube
Oroenteric Feeding Tube
Enterostomy Tube
Standard Tube
Low-profile Tube
Other Tubes
Other Devices
By Age Group
Adult
Pediatric
By End User
Hospital
Ambulatory Care Service
Other End Users
By Application
Oncology
Gastroenterology
Diabetes
Neurological Disorder
Hypermetabolism
Other Applications
India over the Counter Drugs (OTC) Market- Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 74 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 74 pages
- Published: 07-06-2019
Market Overview
The key factors propelling the growth of the Indian over-the-counter drugs market are the shift in consumer attitude toward self-medication, product innovations, and inclination of pharmaceutical companies toward OTC drugs from RX drugs.
India is one of the emerging markets for OTC drugs and offers significant growth potential for the industry. The market is growing in India due to the increasing healthcare expenditure, unhealthy dietary habits, expanding population, and growing healthcare awareness.
The increasing disposable income of people, along with a shift in the consumer attitude toward self-medication and increasing geriatric population are the two major factors driving the overall market in the region. Thus, the increasing awareness about the cost-effectiveness of self-medication and OTC medicines is also a crucial factor fueling the market growth.
There is also the rapidly growing population, which is coupled with the fact that the middle class in these regions is expanding on a large scale, which may add critical mass to the population available to access OTC medication. Thus, the increasing investments of market giants in the emerging market are expected to drive the growth of the overall market.
Scope of the Report
As per the scope of the report, over-the-counter drugs are referred to as the non-prescription drugs. These medicines can be bought by individuals without a doctor’s prescription and are safe for consumption without the doctor’s consent. There are a wide number of therapeutic applications for OTC drugs ranging from weight control drugs to analgesic drugs, and many more.
Key Market Trends
Analgesics is the Segment by Product that is Expected to Grow the Largest During the Forecast Period
Analgesics accounted for a significant value share of the over-the-counter (OTC) drugs market. OTC analgesics are found to have several applications in the treatment of fever, headache, musculoskeletal injuries and disorders, arthritis, and menstrual cramps that have spurred the overall demand in the market. Other factors, such as obesity, stress, and lifestyle disorders lead to chronic pain and different kinds of aches. The population is widespread in the developed markets, as well as in high economic growth countries, such as India, China. Therefore, in these countries, the population contributes to the increasing demand and growth of analgesics in the market.
Competitive Landscape
The industry players are found focusing on new product development and acquisition strategies to gain market share. The developing countries have also opened new growth avenues for pharmaceutical companies. Thus the market has different challenges and requires innovative products facilitating new innovative OTC drugs.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Shift In Consumer Attitude Toward Self Medication
4.2.2 Product Innovations
4.2.3 Inclination of Pharmaceutical Companies Toward OTC Drugs from RX Drugs
4.3 Market Restraints
4.3.1 Price Cuts for Various Ingredients and Restrictions for Advertising
4.3.2 Lack of Specific Regulations for OTC Drugs
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product
5.1.1 Cough, Cold, and Flu Products
5.1.2 Analgesics
5.1.3 Dermatology Products
5.1.4 Gastrointestinal Products
5.1.5 Vitamins, Minerals, and Supplements (VMS)
5.1.6 Other Products
5.2 By Distribution Channel
5.2.1 Retail Pharmacies
5.2.2 Online Pharmacy
5.2.3 Other Distribution Channels
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 GlaxoSmithKline PLC
6.1.2 Emami Limited
6.1.3 Abbott Laboratories
6.1.4 Dabur India Limited
6.1.5 Procter & Gamble
6.1.6 Reckitt Benckiser
6.1.7 Sun Pharmaceuticals Limited
6.1.8 Cipla Inc.
6.1.9 Takeda Pharmaceutical Company
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Product
Cough, Cold, and Flu Products
Analgesics
Dermatology Products
Gastrointestinal Products
Vitamins, Minerals, and Supplements (VMS)
Other Products
By Distribution Channel
Retail Pharmacies
Online Pharmacy
Other Distribution Channels
Infant Nutrition Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 115 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 115 pages
- Published: 07-06-2019
Market Overview
The global infant nutrition market was valued at USD 71.40 billion in 2018 and is estimated to reach USD 98.90 billion in 2024, witnessing a CAGR of 5.58%. There are certain factors propelling the growth of the market, which include the increase in working mother population, higher spending on baby health, and the rising demand for organic baby food.
At present, parents are found spending more on their babies compared to the previous years, owing to several social factors. Presently, children are deemed more worthy of protection than they used to be. According to a number of surveys, parents spend a high amount of money on their babies, sometimes out of guilt, out of shame, or out of social anxiety.
Over the recent years, there has been a remarkable rise that has been observed in the number of young working mothers. This has worked as a key factor in propelling the growth of the infant food nutrition market, as these working mothers are majorly dependent on processed infant nutrition products. Therefore, organic food has been observed to be one of the fastest-growing sectors in the food industry overall, experiencing double-digit growth in most developed markets, compared with a single-digit growth rate for conventional food products. The global demand is increasing, owing to factors, such as the desire of parents to feed their babies healthier foods.
In addition, factors, such as the growth of the middle class, rapid urbanization, and rising rates of female participation in the labor force in many developing markets have encouraged the adoption of convenience-oriented lifestyles, further making prepared baby foods and baby formula more desirable. The increasing middle-class population in the emerging and developing countries has opened new horizons in the infant nutrition market, owing to the fact that the need for products, compatible with a working mom’s schedule, is growing.
In the next few years, it is expected that the global infant nutrition market will show healthy growth. In the last few years, the sale of infant nutrition products in developed countries has shown a single-digit growth rate.
Scope of the Report
Infant nutrition is a substitute food for breast milk. The initial six months after birth plays a very crucial role in the development of a child, wherein ensuring optimal nutrition during this period is of paramount importance. Breast milk is highly nutritious and contains carbohydrates, proteins, fats, minerals, and vitamins imperative for the development of the child. However, in certain cases, the mother may not be able to produce breast milk or may not be able to breastfeed the baby due to other reasons. In such cases, infant nutrition products act as a suitable substitute.
Key Market Trends
Prepared Food is Expected to hold its Highest Market Share in the Baby Food Segment
In the product type segmentation of the infant nutrition market, the prepared food sub-segment under the baby food segment is believed to have the largest market size and is expected to witness a CAGR of 6.51% during the forecast period.
The market size of the baby food segment can be attributed to the current busy lifestyle of people and the emergence of a variety of organic and healthy food for infants. The extensive sale of prepared food is mainly attributed to its ease of access. As the manufacturers of prepared food, most companies are now coming up with more organic food products, which is free from preservatives and residues of fertilizers and pesticides. However, there are also some parents who prefer to prepare the baby’s food by themselves, so as to be assured of hygiene and nutrition.
Therefore there is also a demand for the dried food that is on a rise, majorly due to the increasing trust of parents upon the quality of food, which is provided by the companies and increasing improvisation that is continuously being done in the food products by the manufacturers. There are other baby foods segment of the market majorly inclusive of the juices and products that are rich in omega-3 DHA and arachidonic acid (ARA), along with other nutritional products.
North America is expected to witness the highest CAGR throughout the forecast period
The presence of high per capita healthcare expenditure, coupled with high awareness levels and rising disposable income, is contributing to the growth of the market in the region. The average age at which American women are giving birth has been rising as young women are increasingly prioritizing their careers over family planning. Hence, a rise in parental concerns, with respect to baby’s health and nutrition, is driving the growth of the North American regional market. There are also consumers, especially in the developed countries, who are willing to pay for premium amounts for such products, owing to the general perception of these products being more healthy and safe as compared to conventional products.
Competitive Landscape
There are stringent regulatory scenarios that create high entry barriers for new entrants in the market. As per the data of the China Certification and Accreditation Administration (CNCA), after implementation of quality and safety standards in 2013, out of over 800 foreign brands selling their product of infant formula, only 94 have received approval to sell their products in China, while only two-thirds of the local Chinese manufacturers have received production permit renewals.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increase in Working Mothers Population
4.2.2 Higher Spending on Baby Health
4.2.3 Rising Demand for Organic Baby Food
4.3 Market Restraints
4.3.1 Concerns Regarding Food Safety
4.3.2 Stringent Regulation for Infant Food
4.4 Industry Attractiveness Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product
5.1.1 By Infant Formula
5.1.1.1 First Infant Formula
5.1.1.2 Follow-on Formula
5.1.1.3 Growing-up Formula
5.1.1.4 Specialty Baby Formula
5.1.2 By Baby Food
5.1.2.1 Prepared Food
5.1.2.2 Dried Food
5.1.2.3 Other Baby Foods
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle East & Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle East & Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Baby Gourmet Foods Inc.
6.1.3 Bellamy’s Australia Limited
6.1.4 Danone S.A.
6.1.5 FrieslandCampina
6.1.6 Reckitt Benckiser (Mead Johnson)
6.1.7 Nestlé S.A.
6.1.8 Perrigo Company Plc
6.1.9 Parent’s Choice Infant Formula
6.1.10 The Kraft Heinz Company
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Product
By Infant Formula
First Infant Formula
Follow-on Formula
Growing-up Formula
Specialty Baby Formula
By Baby Food
Prepared Food
Dried Food
Other Baby Foods
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America